• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleNov. 2, 2025, 2:54 PM ESTBy Megan Lebowitz and Gary GrumbachThe Trump administration is staring down a noon deadline on Monday to update a federal judge who ruled late last week that the Agriculture Department must disburse Supplemental Nutrition Assistance Program funds.The deadline comes as tens of millions of Americans continue to go without their November SNAP benefits due to the shutdown, which is just days away from becoming the longest in U.S. history.Across the country, the shutdown’s impact was visible in long lines at food banks. This weekend in Texas and California, stadium parking lots were converted into mass distribution sites where families picked up boxes of produce, frozen meat and other household staples.In the days before the November SNAP funding was expected to run dry, many state governments tried to help fill the gap. Last week, Democratic leaders from 25 states also sued the Agriculture Department, trying to force the department to use contingency funds to keep the program operating as the shutdown continues.The department had previously argued that contingency funds were “not legally available to cover regular benefits,” but were instead supposed to be reserved for situations like natural disasters.On Friday, U.S. District Judge John McConnell of Rhode Island ordered the Trump administration to make a full SNAP payment by the end of the day Monday or a partial payment by Wednesday. In order to make the full SNAP payment, the administration would have to draw on additional funding sources beyond the contingency reserves.“There is no question that the congressionally approved contingency funds must be used now because of the shutdown; in fact, the President during his first term issued guidance indicating that these contingency funds are available if SNAP funds lapse due to a government shutdown,” McConnell wrote in his order, pointing to a 2019 Q&A email written by a SNAP administrator.He ordered the administration to report by noon on Monday “what it will do to comply with this Court’s Order.”McConnell’s ruling came after another federal judge said in a separate case that those suing the administration were “likely to succeed on their claim that Defendants’ suspension of SNAP benefits is unlawful.”U.S. District Judge Indira Talwani of Massachusetts said last week that she will “allow Defendants to consider whether they will authorize at least reduced SNAP benefits for November, and report back to the court no later than Monday, November 3, 2025.”More than 40 million people across the country use SNAP benefits to buy food, raising concerns about how low-income people will put food on the table if the program grinds to a halt.Reached for comment, the White House deferred to the Office of Management and Budget, which did not immediately respond to a request for comment.Agriculture Secretary Brooke Rollins said in an interview on “Fox & Friends Weekend” on Sunday that the contingency fund “won’t even cover about half of what November would cost.”“We are working and looking at all angles right now. The president has been very clear. He wants us to do everything we can to make sure that we can keep these benefits going,” she said.Megan LebowitzMegan Lebowitz is a politics reporter for NBC News.Gary GrumbachGary Grumbach is an NBC News legal affairs reporter, based in Washington, D.C.Aria Bendix , Fiona Glisson and Julie Tsirkin contributed.

admin - Latest News - November 2, 2025
admin
14 views 18 secs 0 Comments




The Trump administration is staring down a noon deadline on Monday to update a federal judge who ruled late last week that the Agriculture Department must disburse Supplemental Nutrition Assistance Program funds



Source link

TAGS:
PREVIOUS
Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleNov. 2, 2025, 6:05 PM ESTBy Andrew GreifIn August, Jacksonville Jaguars kicker Cam Little teased that his leg was strong enough to break the NFL’s record.On Sunday, he did it for real. Little’s 68-yard field goal in the second quarter against Las Vegas — inside the Raiders’ domed stadium — broke the record by two yards, exceeding the 66-yard kick by Baltimore’s Justin Tucker that had stood in the record books since 2021.Little had shown such a kick was possible when he booted a 70-yard field goal during a preseason game in August. Because it was an exhibition, the kick did not officially count as a record. Between that kick and Sunday’s Week 9 record, however, Little had actually struggled to convert long kicks during his second NFL season, making just four of his eight attempts from 40-plus yards, including one of three from 50-plus.Little’s kick came amid a kicking renaissance in the NFL, where during the last two seasons kickers are making 50-plus yard field goals at a higher rate than any point in NFL history. One factor behind that rise is a new rule put in place this season that allowed teams to receive 60 “K-balls” — balls used exclusively by kickers — before the season began. Kickers can then work with those balls to break them in and make them as easy to kick, within the rules, as possible. Previously, teams would only be given three brand-new “K-balls” less than two hours before kickoff.Andrew GreifAndrew Greif is a sports reporter for NBC News Digital. 
NEXT
Nov. 2, 2025, 6:53 PM ESTBy Rohan NadkarniThe Chicago Bears and Cincinnati Bengals played one of the most thrilling games of the NFL season Sunday, a rollercoaster ride that ended with a 47-42 win for the Bears. Joe Flacco threw for 470 yards and four touchdowns in the loss, while Caleb Williams threw for 280 yards and three scores. The teams combined for 31 points in a thrilling fourth quarter — including 28 in the final five minutes. The chaos began with less than six minutes to go. The Bears were leading 34-27 when the Bengals lined up for a 54-yard field goal, only for Evan McPherson to miss the kick short.Two plays later, Chicago wide receiver D.J. Moore was ruled out at the 1-yard line on a running play, but Cincinnati challenged to see if Moore fumbled out of the endzone for a touchback. The Bengals technically won the challenge, but it backfired: The play was overturned to a touchdown, giving the Bears a 41-27 lead.On Cincinnati’s next drive, Flacco brought the offense all the way to the way to the 5-yard line before he was picked off by a diving Tremaine Edmunds, who ran the ball all the way back for a pick-six. Upon review however, Edmunds was ruled down by contact, taking the touchdown off the board.Following the interception, the Bears had a two-score lead with two minutes and 42 seconds to go — a 99.6% win probability, per ESPN. But Chicago went three-and-out in only 27 seconds, giving the Bengals the ball back quickly. Flacco needed only four plays to go 55 yards and find Noah Fant for a 23-yard touchdown. After the Fant score, Cincinnati also converted a two-point conversion to cut the lead to 41-35. After the 2-pointer, the Bengals miraculously recovered an onside kick. The ball didn’t travel 10 yards, but it touched the foot of a Bears player, allowing Cincinnati to pounce on the kick.This time, Flacco drove down the field in six plays, finding Andrei Iosavas for the go-ahead touchdown with only 54 seconds to go.Chicago’s next drive started poorly. Williams threw back-to-back incompletions before finally scrambling for a first on 3rd-and-10, causing the Bears to use their final timeout.That set up a 1st-and-10 for Chicago on its own 42 with 25 seconds to go. On that play, Williams fired a strike to tight end Colston Loveland over the middle of the field. Loveland somehow escaped the grasp of two Bengals, and then outran the rest of the defense for a 58-yard touchdown.Cincinnati had one last possession, but its magic finally ran out when Flacco was intercepted on a Hail Mary attempt on the game’s final play. It was a true up-and-down fourth quarter for the Bears. Their win probability peaked at 99.7% and valleyed at 14.1% — an 85.6% swing. Ultimately, Chicago hung on to improve to 5-3, while the Bengals fell to 3-6. Rohan NadkarniRohan Nadkarni is a sports reporter for NBC News. 
Related Post
October 10, 2025
Trump says mass government layoffs will be 'Democrat oriented'
November 21, 2025
Mamdani and Trump discussed working on affordability
September 25, 2025
Colombian miners rescued after two days underground
September 28, 2025
Sept. 28, 2025, 5:00 AM EDTBy Berkeley Lovelace Jr.Last winter, Brian Noonan read online that some doctors were prescribing an obscure drug, typically given to cancer patients, for autism. Curious, he looked into it for his son Benjamin, who had just been diagnosed with autism in October.“We jumped on it,” Noonan said. “It felt right and it made sense.”The medication was leucovorin, also called folinic acid. It’s a synthetic form of vitamin B9 or folate, which the body needs to make healthy blood cells. During pregnancy, folate is important to reduce the risk of birth defects.Last Monday, the drug was thrust into the national spotlight by President Donald Trump in a rambling press conference about autism that mainly focused on the president and Health Secretary Robert F. Kennedy’s claim that taking acetaminophen during pregnancy could cause autism. Trump briefly mentioned that an “existing drug” — referring to leucovorin — may help with certain symptoms of autism. For those in the autism community, leucovorin is not new. Dr. Richard Frye, a behavioral child neurologist in Phoenix has studied leucovorin and autism for two decades. He made clear that it is not a cure for autism and that more research is needed. He does, however, prescribe it to some people with autism.Noonan’s son Benjamin, who is 4 years old, is one of Frye’s patients. “He’s higher functioning,” Noonan said. “He’s verbal, but he really struggled to put together sentences.” Since starting on the medicine, the family believes Benjamin’s speech has improved, though he still has difficulties with hyperactivity and impulsiveness.Still, Noonan added, he’s under no impression that the drug is a miracle pill. Benjamin also attends a behavioral program preparing him for kindergarten, Noonan said, and he plans to enroll him in speech and occupational therapy. “We very, very much understand we’re still taking an experimental medication,” he said. The Noonan family. Benjamin, 4, who has autism, has used leucovorin.Courtesy of Brian NoonanOther families say the drug conferred larger benefits.Ben Blomgren, of Minneapolis, said his 11-year-old son, Josh, had been prescribed leucovorin off-label in February after he was at risk of being kicked out of school, even as they tried behavioral modification methods.“He’s pretty severe,” Blomgren said. “He didn’t have any language skills. He was not toilet trained.” After starting the medication, Blomgren said Josh’s sleep improved, he’s fully toilet trained and he’s stopped running away from them. “It wasn’t overnight, but we saw major improvement,” he said. Yomarie Miranda, of Florida, said she saw improvements in her 7-year-old son Ethan after he started the medication, including following instructions in class.Ethan was prescribed the medication off label earlier this month, she said.“He’s now looking at me when I speak with him. He’s talking more than before with complete sentences,” she said.A highly unusual moveThe Food and Drug Administration first approved leucovorin in the 1980s to help reduce the toxic side effects of certain chemotherapy drugs.In the decades since, researchers have also studied whether it might treat cerebral folate deficiency (CFD), a neurological condition that makes it harder for folate to reach the brain. Some children with autism also have cerebral folate deficiency, which neurologists say can affect speech, mood and behavior. Last Monday, the FDA said it planned to update the drug’s label to include that use.But the agency’s decision, experts say, rests on just a handful of small studies. And despite Trump’s endorsement, the maker of the brand-name version, GSK, has yet to submit an application to the agency to change the label. In a statement, GSK said it will be submitting the request to expand the approval to include cerebral folate deficiency, though the statement does not mention autism. (Because leucovorin is already an FDA-approved drug, doctors have been able to prescribe it “off label” for other uses, though insurance may not cover it.) It’s a highly unusual move for the FDA: pushing a drug for chemotherapy side effects as a therapy for autism without a formal submission and limited evidence.“It’s incredibly irresponsible,” said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. “For 60-plus years, we’ve counted on the FDA to help patients distinguish between products that work and products that don’t work. And here we saw the FDA making an announcement relying on a summary of unclear data and announcing that they had already decided to approve it.”Alycia Halladay, chief science officer at the nonprofit Autism Science Foundation, was frustrated by the implication that this is a breakthrough in autism research.“It’s not like scientists have just been staring at their belly buttons for 20 years, not looking at autism treatments,” Halladay said in an interview earlier this week. “They have, but the standards have been very high to get [treatments] approved.”Andrew Nixon, a spokesperson for the Department of Health and Human Services, which oversees the FDA, said in a statement: “Analysis across 23 publications from 2009-2024 demonstrated the effectiveness for CFD. Overall, 85% of patients experienced some type of clinical benefit including improved speech/communication capabilities.” Nixon’s statement did not mention autism, and he did not respond to follow-up questions.David Mandell, a psychiatry professor at the University of Pennsylvania, said HHS’ claim that 85% of patients experienced a benefit is a “quite a conceptual leap” because it assumes people with cerebral folate deficiency also have autism.Cerebral folate deficiency “is an extremely rare event, and it is accompanied by symptoms of epilepsy, really severe neurodevelopmental problems and some of those symptoms can look like autism, but it’s not,” he said.“I could not think of a single FDA approval that has such weak evidence in the past 20 years,” Mandell added.Frye, the Phoenix neurologist, estimates up to three-quarters of autistic children have antibodies linked to cerebral folate deficiency, based on his research. Other estimates are much lower: Alycia Halladay, chief science officer at the nonprofit Autism Science Foundation, put the rates at roughly 10% to 30%.The studies on leucovorin are small but look interesting, said Dr. Scott Gottlieb, a former FDA commissioner.“It certainly merits follow up,” Gottlieb said.One of the studies was conducted by Frye: a placebo-controlled trial of more than 40 children with the antibodies, published in Molecular Psychiatry in 2018. It found around two-thirds of kids who got the drug saw improvements in verbal communication after 12 weeks. Others saw no changes. The children all had language impairments, as well as a common type of autism that’s not linked to other neurological diseases.Mandell, however, said the results shouldn’t be taken as evidence.“They claim that in certain subgroups of kids in their already small sample, they find these very large effects,” he said, adding that larger-scale trials that establish clear outcomes ahead of time are needed to verify the results. Kesselheim said it’s important for patients to have access to medications that could have a benefit, especially when there is an unmet medical need. But, he said, there are still a number of unanswered questions.“There is no accurate testing for this,” he said. “What are low folate levels? What are normal folate levels? All of that stuff should be worked out.”Frye said he currently uses two methods to assess whether a child has a folate deficiency: a spinal tap — also known as a lumbar puncture — which involves inserting a needle into the lower back to collect fluid from the spinal cord, and a folate receptor antibody test originally developed for pregnant women that isn’t approved by the FDA for diagnosing folate deficiency in children. Edward Quadros, a research professor at SUNY Downstate Health Sciences University who has worked with Frye studying leucovorin for autism, said parents are already trying the drug, including supplement versions, which aren’t regulated and can be dangerous.“By making the FDA approve it, and reputable pharmaceutical companies manufacturing it and selling it, at least it gives you quality dosing,” Quadros said.Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.Aria Bendix contributed.
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved